Institutional members access full text with Ovid®

Share this article on:

The cholesterol ester transfer protein inhibitor, anacetrapib

Jialal, Ishwarlal; Kaur, Jaspreet

Section Editor(s): Rees, Alan


In the editorial that appeared on page 245 of the June 2011 issue, the below annotation was omitted from reference 7.

••In this study of 1623 patients with CVD or CVD risk equivalents (Framingham risk score of 20% over 10 years) Cannon et al. show that compared to placebo, Anacetrapib at a dose of 100 mg/d results in a 39.8 % reduction in LDL-Cholesterol and a 138 % increase in HDL-Cholesterol. There were commensurate changes in both apolipoprotein B and apolipoprotein A1 levels. There was no signal for increase BP. Also aldosterone, bicarbonate and potassium levels were similar compared to placebo and there was no increase in prespecified adjudicated cardiovascular end points.

Current Opinion in Lipidology. 22(4):326, August 2011.

Current Opinion in Lipidology: June 2011 - Volume 22 - Issue 3 - p 245–246
doi: 10.1097/MOL.0b013e3283474ce1
Bimonthly update: Edited by Alan Rees